Skip to main content

Table 1 Studies on Haploidentical Hematopoietic Stem Cell Transplantation

From: Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

Patients(n)

Disease

Conditioning

Graft/ Manipulation

GVHD Prophylaxis

GF

aGVHD

cGVHD

TRM

LFS/DFS

Nation

Reference

104

AL

ST:TBI/thiotepa/fludarabine/ATG

PB/CD34+ selection

No

1st 6.9%

(II-IV)7.9%

7.1%

36.5%

AL CR:46%-48%

Italy

Aversa

(2005)[8]

49

AL/MDS/ CML/MPD

RIC: Flu+Cy/ anti-CD52

PB/anti-CD52

CsA+MMF

6%

(II-IV)16%

14%

10.2%

31-63%@1-3 year

U.S.A

Rizzieri

(2007)[10]

24

AL/AA

ST:TBI/CY

BM/costimulatory blockade

CsA+MTX

5%

(III-IV)23.8%

8.3%

50%

33%@7 years

U.S.A

Guinan

(2008)[11]

60

AL/NHL/ CML/MM

RIC:Flu/Mel/OKT-3/thiotepa

PB/CD3+CD19 depletion

No if CD3+T < 5 × 104/kg

0

(II-IV)47%

15%

25%@100 days

44%@7 years

HR 41%@1 year 24%@2 years

Germany

Federmann

(2009)[12]

66

AL/MDS

RIC:TBI/flu/Bu/ATG/melphalan

PB or BM/No

FK506

6.1%

(II-IV)38%

33.3%

59.1%

28.8%@4 years

Japan

Kurokawa

(2010)[13]

820

AL/CML/ NHL/AA

ST:Bu/Cy/Ara-C/MeCCNU/ATG

BM+PB/No

CsA+MTX +MMF

< 1%

(II-IV)42.9%

(III-IV)14.0%

Total 53.7%

Ex 23.4%

@2 years

21%@2 years

SR68.1% HR47.1%

@2 years

China

Huang

(2011)[14]

83

AL/MDS

RIC:Bu/Flu/ATG

PB/No

CsA+MTX

0

24%

28%

17%@1 year

AML/MDS

CR53%-60%;

AML RE9%

Korea

Lee

(2011)[15]

50

AL/MDS

RIC:Cy/Flu/TBI

BM/No

Cy(HD)+ FK506+MMF

4%

(II-IV)32%

13%

7%@1 year

46%@1 year

U.S.A

Fuchs

(2011)[9]

21

AL/CML

ST:Bu/Cy/ MeCCNU/ATG

PB/No

CsA+MTX +MMF

0

(II-IV)33.8%

39.5%

20%@2 years

55.6%@2 years

China

Yu

(2012)[16]

  1. HLA Human leukocyte antigen; AL Acute Leukemia; CML chronic myelogenous leukemia; MDS myelodysplastic syndrome; ST Standard intensity/Myeloablative; RIC reduced intensity; Bu Busulfan; Cy cyclophosphamide; Ara-C aracytidine; TBI total-body irradiation; MeCCNU Semustine; CsA cyclosporine A; MMF Mycophenolate mofetil; Flu fludrabine; ATG antithymocyte globulin; FK506 Tacrolimus; anti-CD52 alemtuzumab; GF graft failure; HR high risk; SR standard risk; Re refractory; Ex extensive; GVHD Graft versus host disease